A simple and robust model to predict the inhibitory activity of α-glucosidase inhibitors through combined QSAR modeling and molecular docking techniques

[11] Narender T(2017)-glucosidase inhibitors with in vivo antidiabetic effect Chem Eng Res Des 120 15-25

[12] Madhur G(2017)Discovery of novel J Mol Liq 240 196-208

[13] Jaiswal N(2017)-glucosidase inhibitors based on the virtual screening with the homology-modeled protein structure J Mol Liq 225 521-530

[14] Agrawal M(2020)Docking and QSAR analysis of tetracyclic oxindole derivatives as Mol Divers 33 388-396

[15] Maurya CK(2016)-glucosidase inhibitors J Nat Gas Sci Eng 203 139-150

[16] Rahuja N(2018)New novel Chemosphere 16 7185-7192

[17] Srivastava AK(2008)-glucosidase inhibitors produced by microbial conversion Bioorg Med Chem 97 118-126

[18] Tamrakar AK(2009)Design and synthesis of 2, 6-di (substituted phenyl) thiazolo [3, 2-b]-1, 2, 4-triazoles as Chemom Intell Lab Syst 59 33-44

[19] Dinparast L(2016)-glucosidase and J Taiwan Inst Chem Eng 5 231-243

[20] Valizadeh H(2000)-amylase inhibitors, co-relative pharmacokinetics and 3D QSAR and risk analysis Mol Divers 43 579-586

[11] Narender T(2017)-glucosidase inhibitors with in vivo antidiabetic effect Chem Eng Res Des 120 15-25

[12] Madhur G(2017)Discovery of novel J Mol Liq 240 196-208

[13] Jaiswal N(2017)-glucosidase inhibitors based on the virtual screening with the homology-modeled protein structure J Mol Liq 225 521-530

[14] Agrawal M(2020)Docking and QSAR analysis of tetracyclic oxindole derivatives as Mol Divers 33 388-396

[15] Maurya CK(2016)-glucosidase inhibitors J Nat Gas Sci Eng 203 139-150

[16] Rahuja N(2018)New novel Chemosphere 16 7185-7192

[17] Srivastava AK(2008)-glucosidase inhibitors produced by microbial conversion Bioorg Med Chem 97 118-126

[18] Tamrakar AK(2009)Design and synthesis of 2, 6-di (substituted phenyl) thiazolo [3, 2-b]-1, 2, 4-triazoles as Chemom Intell Lab Syst 59 33-44

[19] Dinparast L(2016)-glucosidase and J Taiwan Inst Chem Eng 5 231-243

[20] Valizadeh H(2000)-amylase inhibitors, co-relative pharmacokinetics and 3D QSAR and risk analysis Mol Divers 43 579-586